Trial · NCT03951961
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
NCT03951961, Phase 2, Terminated, University of Jena
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation. Trials, record NCT03951961. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03951961
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
- NCT number
- NCT03951961
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- University of Jena
- Conditions
- Acute Myeloid Leukemia, Adult
- Interventions
- Midostaurin
- First posted
- 2019-05-16
- Last updated
- 2022-01-21
- Other registries' IDs
- eudract:2019-000136-26
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | proportion of patients without AML relapse | at 12 months after start of midostaurin treatment | impact of midostaurin single treatment on Leukemia-free survival (LFS) |
| Secondary | number of patients with low MRD (Minimal Residual Disease) | at 3 months after start of midostaurin treatment | molecular response to midostaurin treatment |
| Secondary | Incidence of acute and chronic graft-versus-host disease (GvHD) | baseline and every 3 months until 12 months after start of midostaurin treatment | Incidence of acute and chronic GvHD |
| Secondary | Incidence of adverse events grade 3-5 of midostaurin after allogeneic SCT | baseline and every 3 months until 12 months after start of midostaurin treatment | Incidence of adverse events grade 3-5 |
| Secondary | Next-generation sequencing analyses of FLT3-mutation | baseline and every 3 months until 12 months after start of midostaurin treatment | mechanisms of primary or secondary resistance to midostaurin |
| Secondary | quality of life assessment with certified "EORTC QLQ - C30 questionnaire" | baseline and every 3 months until 12 months after start of midostaurin treatment | quality of life assessment with certified "EORTC QLQ - C30 questionnaire" |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03951961
GET https://conductscience.org/api/trials/v1/NCT03951961/registered